Evaluation of Fosfomycin Activity Against Extended Spectrum Beta Lactamase (ESBL) Producing Enterobacteriaceae Isolated from Three Centers of Tehran, Iran.

Q3 Medicine

Recent patents on anti-infective drug discovery Pub Date : 2018-01-01 DOI:10.2174/1574891X13666180517075803

Roya Ghanavati, Elnaz Ohadi, Hossein Kazemian, Fateme Yazdani, Alireza Torki, Behrooz S Kalani, Gholamreza Irajian

{"title":"Evaluation of Fosfomycin Activity Against Extended Spectrum Beta Lactamase (ESBL) Producing Enterobacteriaceae Isolated from Three Centers of Tehran, Iran.","authors":"Roya Ghanavati, Elnaz Ohadi, Hossein Kazemian, Fateme Yazdani, Alireza Torki, Behrooz S Kalani, Gholamreza Irajian","doi":"10.2174/1574891X13666180517075803","DOIUrl":null,"url":null,"abstract":"Background: Rising rates of antimicrobial resistance among Enterobacteriaceae limit the use of reliably active forms of available drugs. The aim of this study was to investigate the prevalence of fosfomycin (US6794490B2) resistance gene among ESBL producing isolates in Iran.Method: We tested 355 isolates of Enterobacteriacea collected from various clinical samples including urine, wounds, blood and other sources during June 2016 to July 2017. Antibiotic sensitivity and Extended Spectrum Beta Lactamase (ESBL) production were tested using agar dilution method according to the Clinical and Laboratory Standards Institute (CLSI) guidelines. ESBL genes (blaTEM, bla SHV,bla CTX-M), plasmid-encoded fosfomycin resistance genes (fosA, fosB, fosA3 and fosC2) and chromosomal mutations (murA, glpT, uhpT) were detected by Polymerase Chain Reaction (PCR).Results: In this study, 151 of the 355 isolates were ESBL-positive. blaCTX-M (77%) was the most common gene followed by blaSHV (70%) and blaTEM (58%), either alone or in combination. Eighty nine percent (132/151) of the ESBL-positive isolates were MDR. Antimicrobial susceptibility rates were higher for fosfomycin (92.8%) and imipenem (35.5%) among ESBL-positive isolates. None of the ESBL- positive isolates harbored any mutations or plasmid-mediated fosfomycin resistance determinants.Conclusion: In conclusion, fosfomycin showed good antimicrobial activity against multidrug resistance ESBL- positive Enterobacteriaceae.","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent patents on anti-infective drug discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1574891X13666180517075803","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 3

Abstract

Background: Rising rates of antimicrobial resistance among Enterobacteriaceae limit the use of reliably active forms of available drugs. The aim of this study was to investigate the prevalence of fosfomycin (US6794490B2) resistance gene among ESBL producing isolates in Iran.

Method: We tested 355 isolates of Enterobacteriacea collected from various clinical samples including urine, wounds, blood and other sources during June 2016 to July 2017. Antibiotic sensitivity and Extended Spectrum Beta Lactamase (ESBL) production were tested using agar dilution method according to the Clinical and Laboratory Standards Institute (CLSI) guidelines. ESBL genes (blaTEM, bla SHV,bla CTX-M), plasmid-encoded fosfomycin resistance genes (fosA, fosB, fosA3 and fosC2) and chromosomal mutations (murA, glpT, uhpT) were detected by Polymerase Chain Reaction (PCR).

Results: In this study, 151 of the 355 isolates were ESBL-positive. blaCTX-M (77%) was the most common gene followed by blaSHV (70%) and blaTEM (58%), either alone or in combination. Eighty nine percent (132/151) of the ESBL-positive isolates were MDR. Antimicrobial susceptibility rates were higher for fosfomycin (92.8%) and imipenem (35.5%) among ESBL-positive isolates. None of the ESBL- positive isolates harbored any mutations or plasmid-mediated fosfomycin resistance determinants.

Conclusion: In conclusion, fosfomycin showed good antimicrobial activity against multidrug resistance ESBL- positive Enterobacteriaceae.

查看原文本刊更多论文

磷霉素对伊朗德黑兰三个中心产肠杆菌科扩展谱β -内酰胺酶(ESBL)的活性评价

背景:肠杆菌科抗生素耐药性的上升限制了现有药物的可靠活性形式的使用。本研究的目的是调查伊朗产ESBL分离株中磷霉素(US6794490B2)耐药基因的流行情况。方法:对2016年6月至2017年7月收集的尿、伤口、血液等临床样本中分离的355株肠杆菌进行检测。根据临床和实验室标准协会(CLSI)的指南，采用琼脂稀释法检测抗生素敏感性和扩展谱β -内酰胺酶(ESBL)的产生。聚合酶链反应(PCR)检测ESBL基因(blaTEM、bla SHV、bla CTX-M)、质粒编码磷霉素耐药基因(fosA、fosB、fosA3和fosC2)和染色体突变(murA、glpT、uhpT)。结果:本研究355株分离株中有151株为esbl阳性。blaCTX-M(77%)是最常见的基因，其次是blaSHV(70%)和blaTEM(58%)，无论是单独的还是联合的。89% (132/151) esbl阳性分离株为耐多药。essl阳性分离株对磷霉素和亚胺培南的敏感性较高(分别为92.8%和35.5%)。ESBL阳性分离株中没有任何突变或质粒介导的磷霉素耐药决定因素。结论:磷霉素对多药耐药ESBL阳性肠杆菌具有良好的抑菌活性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Recent patents on anti-infective drug discovery Medicine-Pharmacology (medical)

CiteScore

2.40

自引率

0.00%

发文量

期刊介绍： Recent Patents on Anti-Infective Drug Discovery publishes review articles on recent patents in the field of anti-infective drug discovery e.g. novel bioactive compounds, analogs & targets. A selection of important and recent patents on anti-infective drug discovery is also included in the journal. The journal is essential reading for all researchers involved in anti-infective drug design and discovery.